BioSpace News Archive

Seno Medical’s Imagio® Breast Imaging System has been named a finalist in the 2022 Edison Awards competition in the Science and Medical category and Diagnostics sub-category.

Qurient Co. Ltd. (KRX: 115180), a clinical stage biotech company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for Q901, a small molecule oncology drug candidate targeting cyclin dependent kinase 7 (CDK7).

On Q Recruitment releases the 2021 Job Satisfaction & Salary Report, highlighting the latest workplace and employment trends in the post-pandemic climate.

BlueSphere Bio announced that David Apelian, M.D., Ph.D., MBA, chief executive officer of BlueSphere Bio, will present an in-person company overview at the 2022 BIO CEO & Investor Forum being held Monday, February 14 – Thursday, February 17, 2022.

DuPont has launched a new online sales portal tailored to the needs of bioprocessing industry purchasers. The portal handles online sales transactions, with target lead times of < 1 week.

Texas Medical Center Innovation (TMCi) today announced the 2022 Accelerator for Cancer Therapeutics annual cohort, comprised of Texas-based startups working to address the world’s most significant cancer challenges with novel technologies and treatments.

Amgen outlined its growth strategy through 2030, a period during which the Company expects to deliver attractive financial performance by serving many more patients globally than it does today, both with its current portfolio of marketed medicines and with the numerous new medicines it is advancing through its pipeline.

Morphocell Technologies Inc. announces the development of an innovative, scalable method for generating cells that may enable future cell therapies for liver diseases and improve the way these conditions are studied in the lab and how future medications for other illnesses are developed.

A research team at Rosalind Franklin University of Medicine and Science has developed a promising new therapeutic approach for the treatment of cystic fibrosis, a devastating lung and multi-system disease caused by mutations in a gene called CFTR.

Abivax will be hosting a Satellite Symposium on February 17, 2022, at 12:00-1:00 pm CET (6:00-7:00am ET) on ABX464’s potential to address unmet medical needs for the treatment of ulcerative colitis (UC).